N*-N*-S* tridentate ligand system as potential antitumor agents

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Pharmacology

Background:

• Antitumor drug discovery is crucial for treating various cancers.
• Development of novel compounds with unique ligand structures is an active area of research.
• Tridentate ligands, particularly those incorporating N and S heteroatoms, offer diverse coordination possibilities for therapeutic applications.

Purpose of the Study:

• To synthesize and evaluate novel compounds featuring an N*-N*-S* tridentate ligand for potential antitumor properties.
• To identify specific compounds with significant cytotoxic effects against cancer cell lines and in vivo models.
• To establish a structure-activity relationship for this class of compounds in cancer treatment.

Main Methods:

• Synthesis of a series of compounds incorporating the N*-N*-S* tridentate ligand framework.
• In vivo testing of synthesized compounds for antitumor activity against P-388 lymphocytic leukemia in mice.
• In vitro evaluation of promising compounds against L-1210 and S180 cancer cell lines.

Main Results:

• Several N*-N*-S* tridentate ligand-containing compounds were synthesized.
• 2,2 -bipyridyl-6-carbothioamide (1a) exhibited notable antitumor activity in mice against P-388 lymphocytic leukemia at high doses.
• Compound 1a demonstrated significant cytotoxic activity against L-1210 and S180 cancer cells in culture.

Conclusions:

• The synthesized N*-N*-S* tridentate ligand scaffold shows promise for developing new anticancer agents.
• 2,2 -bipyridyl-6-carbothioamide is a lead compound with demonstrated in vitro and in vivo antitumor potential.
• Further investigation into compound 1a and related structures is warranted for cancer therapy development.